ALK and lung cancer: Although GEM models for EML4‐ALK lung cancer were first established in 2008 (Soda et al, 2008), the use of GEM models to assess the in vivo potency of ALK TKIs was limited due to technical challenges (Chen et al, 2010, 2014).